ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2229

National Multicenter study of Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease: effectiveness and progressive lung disease

Ana Serrano-Combarro1, Belén Atienza-mateo2, Jesús Loarce3, César Antonio Egües Dubuc4, Marta Pastor Mena5, Rafael B. Melero-González6, Sara Maria Rojas Herrera7, Carmen Carrasco-Cubero8, Carolina Perez Garcia9, Juan María Blanco-Madrigal10, Nuria Vegas Revenga11, Deseada Palma-Sanchez12, Andrea García-Valle13, Virginia Ruiz-Esquide14, Jose Ramón Lamua-Riazuelo15, Santos Castañeda16 and Ricardo Blanco17, 1Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, 3Ramón y Cajal University Hospital, Madrid, Spain, 4Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, 5Hospital de Jerez de la Frontera, Jerez de la Frontera, Spain, 6COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, 7Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, 8Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 9Hospital del Mar, Barcelona, Spain, 10Rheumatology. Hospital Universitario Araba., Vitoria, Pais Vasco, Spain, 11Galdakao- Usansolo University Hospital, Galdakao, Spain, 12Rheumatology. Hospital Rafael Méndez, Lorca, Murcia, Spain, 13Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, 14Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, 15Hospital Universitario del Henares, Madrid, Spain, 16Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 17Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

Meeting: ACR Convergence 2025

Keywords: ,

Session Information

Date: Tuesday, October 28, 2025

Title: (2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) in Rheumatoid Arthritis (RA) determines a worse prognosis with an increased mortality. Abatacept and rituximab may be the preferred therapies. JAK inhibitors (JAKi) have demonstrated effectiveness in observational studies of RA-ILD, especially with tofacitinib or baricitinib (BARI). While both articular and pulmonary domains may respond to JAKi, some patients experience ILD progression. Identifying this subgroup of patients is essential for early detection and appropriate management. In a large series of RA-ILD patients treated with BARI, we aimed to a) study the effectiveness, and b) characterize the subgroup with progressive ILD.

Methods: From a large observational multicenter study of 72 RA-ILD patients treated with BARI, we selected those with available pulmonary function tests (PFTs) follow-up data. Progressive ILD was defined as an absolute decline of forced vital capacity (FVC) of ≥10% within 1 year of follow-up since BARI initiation (Figure). We compared patients with and without progressive ILD. Results are expressed as percentage, mean±SD or median [IQR], as appropriate.

Results: A total of 42 patients with available data on FVC evolution were included. Progressive and non-progressive ILD was observed in 11 (26%) and 31 (74%) patients, respectively. The baseline general features are summarized in Table. Both groups were similar in age, smoking, positivity of rheumatoid factor or anti-citrullinated protein autoantibodies, ILD duration up to BARI initiation, prednisone dose, baseline PFTs or radiological pattern. Progressive ILD was more frequent in women and as expected required more combined treatment with antifibrotics. FVC evolution in both groups (progressive and non-progressive ILD) and by sex is displayed in figure.

Conclusion: BARI may be useful in RA-ILD. However, progression may be present in around a quarter of patients, especially in women. Effectiveness should be closely monitored with PFTs to early detect progressive ILD.

Supporting image 1Table. Baseline characteristics of RA-ILD patients treated with BARI.

Supporting image 2Figure. FVC evolution in A) both groups (progressive and non-progressive ILD) and B) by sex. Progressive ILD was defined as an absolute decline of forced vital capacity (FVC) of ≥10% within 1 year of follow-up since BARI initiation).

Disclosures: A. Serrano-Combarro: None; B. Atienza-mateo: None; J. Loarce: None; C. Egües Dubuc: None; M. Pastor Mena: None; R. Melero-González: None; S. Rojas Herrera: None; C. Carrasco-Cubero: None; C. Perez Garcia: None; J. Blanco-Madrigal: None; N. Vegas Revenga: None; D. Palma-Sanchez: None; A. García-Valle: None; V. Ruiz-Esquide: None; J. Lamua-Riazuelo: None; S. Castañeda: None; R. Blanco: AbbVie/Abbott, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Janssen, 2, 6, Merck/MSD, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 5, 6.

To cite this abstract in AMA style:

Serrano-Combarro A, Atienza-mateo B, Loarce J, Egües Dubuc C, Pastor Mena M, Melero-González R, Rojas Herrera S, Carrasco-Cubero C, Perez Garcia C, Blanco-Madrigal J, Vegas Revenga N, Palma-Sanchez D, García-Valle A, Ruiz-Esquide V, Lamua-Riazuelo J, Castañeda S, Blanco R. National Multicenter study of Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease: effectiveness and progressive lung disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/national-multicenter-study-of-baricitinib-in-rheumatoid-arthritis-interstitial-lung-disease-effectiveness-and-progressive-lung-disease/. Accessed .

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/national-multicenter-study-of-baricitinib-in-rheumatoid-arthritis-interstitial-lung-disease-effectiveness-and-progressive-lung-disease/